Acute inflammation is an immune response to a pathogen, irritant, or injury to remove whatever has caused the response, dispose of damaged tissue, and initiate healing. Resident immune cells at the site of insult recognize pathogen-associated molecular patterns (PAMPS) or damage-associated molecular patterns (DAMPS) and release various inflammatory mediators. Initial responses include vasodilation, increased vascular permeability, and extravasation of leukocytes. Mediators of inflammation include bradykinins, the complement system, cytokines, chemokines, leukotrienes, and prostaglandins among others. Chronic inflammation is characterized by infiltration of the tissue site by macrophages and lymphocytes leading to overall tissue damage. Chronic inflammatory diseases include diabetes, cardiovascular diseases, arthritis, allergies, cancer, and chronic obstructive pulmonary disease.
MCC-950 is an inhibitor of the NLRP3 and AIM2 inflammasome
OLT1177 is a potent and specific inhibitor of the NLRP3 inflammasome
Non-selective inhibitor of S9 family proteases that activates the NLRP1B inflammasome
Rocaglamide is a potent inhibitor of NF-κB activation
Potent natural product inhibitor of NF-κB
Parthenolide derivative that inhibits NF-κB
Rofecoxib is a potent and selective COX-2 inhibitor
Clinically useful non-selective COX inhibitor
Celecoxib is a potent and selective COX-2 inhibitor
Zileuton is a reversible inhibitor of 5-lipoxygenase
MK-866 blocks leukotriene biosynthesis via inhibition of FLAP